Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Examining Fetal Outcomes Following Prenatal Opioid and Cannabis Exposure
EF 2023-24
Résumé
Buprenorphine, an opioid agonist, is used as a harm reduction strategy to stabilize plasma concentrations in patients with opioid-use disorders during pregnancy. It causes less adverse outcomes than illicit drugs to the fetus. Pregnant individuals using opioids often simultaneously use other drugs, with cannabis being the most prevalent. Both opioids and cannabis act on important receptors in the fetal brain, making them vulnerable to perturbed nervous system development. The concurrent effects of both opioids and cannabis on fetal development are not well known. I hypothesize that eliminating cannabis exposure in pregnant individuals with opioid-use disorders, as well as transitioning them to opioid agonist therapy, will lead to improvements in motor, social, learning and memory functions for the fetus. My research will investigate the impact of opioid to opioid agonist therapy conversion in the presence and absence of cannabis on offspring cognitive functions. Using a mouse model, I will investigate two harm reduction strategies: (1) transferring pregnancies from opioids to an opioid agonist (2) removing cannabis exposure from simultaneous illicit opioid and opioid agonist exposure. A series of neurocognitive tests will be used to assess social behavior, learning, memory, and sensorimotor skills in the offspring. I will also characterize fetal cellular response from opioid to opioid agonist therapy conversion. In sacrificed offspring from the previously described harm reduction strategies, sections of the brain will be prepared for histological investigations. This study will contribute to our understanding of drug use during pregnancy and provide valuable insights for harm reduction strategies and public health interventions.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506272
Name
Pisanko Anastasia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Examining Fetal Outcomes Following Prenatal Opioid and Cannabis Exposure
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cannabis Exposure; Developmental Origins Of Health And Disease; Fetal Cognitive Functions; Fetal Programming; Harm Reduction; Opioid Agonist Therapy; Perinatal Drug Exposure; Substance Use Disorder
Abstract
Buprenorphine, an opioid agonist, is used as a harm reduction strategy to stabilize plasma concentrations in patients with opioid-use disorders during pregnancy. It causes less adverse outcomes than illicit drugs to the fetus. Pregnant individuals using opioids often simultaneously use other drugs, with cannabis being the most prevalent. Both opioids and cannabis act on important receptors in the fetal brain, making them vulnerable to perturbed nervous system development. The concurrent effects of both opioids and cannabis on fetal development are not well known. I hypothesize that eliminating cannabis exposure in pregnant individuals with opioid-use disorders, as well as transitioning them to opioid agonist therapy, will lead to improvements in motor, social, learning and memory functions for the fetus. My research will investigate the impact of opioid to opioid agonist therapy conversion in the presence and absence of cannabis on offspring cognitive functions. Using a mouse model, I will investigate two harm reduction strategies: (1) transferring pregnancies from opioids to an opioid agonist (2) removing cannabis exposure from simultaneous illicit opioid and opioid agonist exposure. A series of neurocognitive tests will be used to assess social behavior, learning, memory, and sensorimotor skills in the offspring. I will also characterize fetal cellular response from opioid to opioid agonist therapy conversion. In sacrificed offspring from the previously described harm reduction strategies, sections of the brain will be prepared for histological investigations. This study will contribute to our understanding of drug use during pregnancy and provide valuable insights for harm reduction strategies and public health interventions.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pisanko, Anastasia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~